⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 15, 2024Open Access

Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Aditya Bardia Sheng Sun Nayana Thimmiah James T. Coates Bogang Wu Rachel O. Abelman Laura M. Spring Beverly Moy Phoebe Ryan Mark N. Melkonyan Ann H. Partridge Dejan Juric Jeffrey Peppercorn Heather A. Parsons Seth A. Wander Victoria Attaya Brenda Lormil Maria Shellock Aiko Nagayama Veerle Bossuyt Steven J. Isakoff Sara M. Tolaney Leif W. Ellisen

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Figure S4. Results of phase 1b clinical trial of SG and talazoparib

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bardia et al. (2024) studied this question.

synapsesocial.com/papers/68e60477b6db6435875983d9 https://doi.org/10.1158/1078-0432.26302815

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024
2Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024 · 1 citations
3Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024
4Data from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024
5Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024 · 55 citations

Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.2024
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.2024
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial2024